| Sandoz Pharmaceuticals AG - Estalis 50/250, transdermale Pflaster |
| 54704 | | 02 | | Estalis 50/250 | | transdermale Pflaster | | G03FA01 | | Norethisterone and Estrogen | | 17.08.1999 | | |
|
| Composition |
| estradiolum 0.496 mg ut estradiolum hemihydricum 0.512 mg, norethisteroni acetas 4.8 mg, silicone adhesive, acrylic adhesive, povidonum K 30, acidum oleicum, dipropylenglycolum, Trägermaterial: ad praeparationem pro 16 cm², cum liberatione 50 µg et 250 µg/24 h. |
| Packungsbestandteile |
| Transdermal patch | | | | | Active Agent | Dose |
|---|
| Estradiol | 0.496 mg | | Norethisterone Acetate | 4.8 mg |
| | BAG: Active Agent | Dose |
|---|
| Estradiol | 0.496 mg | | Norethisterone Acetate | 4.8 mg |
| | | | Inactive agents | Dose | additional_information |
|---|
| Acidum Oleicum | | | | Acrylic Adhesive | | | | Ad Praeparationem | 16 cm | Trägermaterial | | Cum Liberatione | 50µg et 250 µg / 24h | | | Dipropylenglycol | | | | Povidonum K | 30 | | | Silicone Adhesive | | |
| |
|
|
